- Home
- VIVS vs JAGX Comparison
VIVS vs JAGX Comparison
Compare VIVS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- JAGX
- Stock Information
- Founded
- VIVS 2007
- JAGX 2013
- Country
- VIVS United States
- JAGX United States
- Employees
- VIVS N/A
- JAGX N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- JAGX Health Care
- Exchange
- VIVS Nasdaq
- JAGX Nasdaq
- Market Cap
- VIVS 4.2M
- JAGX 3.5M
- IPO Year
- VIVS N/A
- JAGX N/A
- Fundamental
- Price
- VIVS $1.45
- JAGX $2.58
- Analyst Decision
- VIVS
- JAGX Strong Buy
- Analyst Count
- VIVS 0
- JAGX 1
- Target Price
- VIVS N/A
- JAGX $60.00
- AVG Volume (30 Days)
- VIVS 64.3K
- JAGX 90.6K
- Earning Date
- VIVS 07-07-2025
- JAGX 08-12-2025
- Dividend Yield
- VIVS N/A
- JAGX N/A
- EPS Growth
- VIVS N/A
- JAGX N/A
- EPS
- VIVS N/A
- JAGX N/A
- Revenue
- VIVS $144,000.00
- JAGX $11,552,000.00
- Revenue This Year
- VIVS $42.38
- JAGX $22.41
- Revenue Next Year
- VIVS $15.42
- JAGX $30.00
- P/E Ratio
- VIVS N/A
- JAGX N/A
- Revenue Growth
- VIVS 32.11
- JAGX 13.93
- 52 Week Low
- VIVS $1.41
- JAGX $2.43
- 52 Week High
- VIVS $21.96
- JAGX $110.75
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- JAGX 28.76
- Support Level
- VIVS N/A
- JAGX $2.61
- Resistance Level
- VIVS N/A
- JAGX $3.30
- Average True Range (ATR)
- VIVS 0.00
- JAGX 0.28
- MACD
- VIVS 0.00
- JAGX 0.06
- Stochastic Oscillator
- VIVS 0.00
- JAGX 6.56
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.